How are biopharma’s commercial teams really using AI and is it working? That is the question Evaluate set out to answer by partnering with BioPharma Dive to survey 150 senior decision-makers across the US, UK and Canada, representing companies with over $100 million in annual revenue and a broad range of commercial functions.
The findings are striking. Confidence in AI is high across the industry. But when you look at what that confidence is based on, the tools being used, the data those tools are trained on, and the results teams are actually reporting a more complicated picture emerges.
This report covers seven key findings across the commercial functions where AI is being adopted fastest including forecasting, competitive intelligence, dealmaking and portfolio strategy. It examines not just what teams are doing with AI today, but where the gaps are, what the risks look like in practice, and what the next three years are likely to bring.
For pharma companies assessing their own AI strategy, and for investors tracking how the commercial side of the market is evolving, this is essential context.
This report findings include:
- 97% of executives agree AI improves decision-making – but only 9% call it transformational.
- 95% of biopharma companies rely on general-purpose AI tools like ChatGPT.
- 69% trust AI forecasts more than traditional ones, yet accuracy ranks low as a benefit.
- AI is being tested across multiple use cases, but ROI remains uneven.
- 71% believe AI will have greater influence over portfolio strategy in future.
